2014 Should Represent The Year Of Going “Pivotal” For Stemline, Says Roth Capital
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) and a price target of $62.00, following an update from STML’s management regarding its clinical plans for its two lead products, SL-401 and SL-701, which was provided to Roth Capital.
“Management provided us with an important update regarding its clinical plans for its two lead products, SL-401 and SL-701. With commercial scale GMP manufacturing in place, the SL-401 program will push forward into rare hematological tumors, led by BPDCN, with subsequent efforts in AML. The SL-701 program in glioblastoma is currently screening patients for its randomized Phase II in 2nd-line patients and will use an enhanced product”, said Pantginis.
The analyst continued: “We believe 2014 should represent the year of going “pivotal” for Stemline, but of course, the ultimate registration path will be based on clinical data and discussions with the FDA. The SL-401 program has been tweaked to “double down” on ultra orphan indications with subsequent efforts in AML. The company is on the verge of filing its IND and will be in continuing discussions with the FDA in 2H14 into next year as the clinical program progresses. The focus in rare diseases will still be anchored by the planned BPDCN program (high response rates to date) which will likely enroll ~40-50 patients in N. America and E.U. with response rate as the primary endpoint”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Joseph Pantginis currently has an average return of -7.8% and a 31% success rate. Pantginis has a -45.9% average profit recommending STML, and he is ranked #3079 out of 3135 analysts.